Celcuity enters the back half of July with a striking divergence: analysts are raising price targets while a heavy short base refuses to budge, setting up a tug-of-war that the August 14 earnings date will likely resolve.
The short side of the trade remains substantial. Short interest runs at 23.4% of the free float — roughly one in every four tradeable shares is sold short, a level that has crept 5% higher over the past month. Yet the borrow market tells a more complicated story. Availability has loosened sharply this week, jumping 40% to sit at around 110% of current short interest — meaning lenders now hold roughly as many shares available to borrow as are already out on loan. Cost to borrow has fallen to just 0.59%, its lowest level in two months. Those two data points together describe a short base that is large but not squeezed: existing shorts are comfortable, and new entrants face no meaningful friction in opening positions. The ORTEX short score of 76 confirms the bearish lean is elevated relative to the broader market, though it has eased slightly from its mid-week peak near 77.4.
Options positioning has turned more defensive than it was a month ago. The put/call ratio has drifted up to 0.80, sitting roughly one standard deviation above its 20-day average of 0.68 — a modest tilt toward downside protection rather than an outright alarm signal. For context, the 52-week low on the PCR was 0.09; bulls were far more aggressive not long ago. The current setup suggests investors are hedging rather than speculating, which fits a stock that has rallied 25% over the past month yet still carries a short interest above 23%.
The Street is clearly in the bull camp. Nine analysts carry buy-equivalent ratings with no bears in the published consensus, and the mean price target of $163 implies roughly 47% upside from Tuesday's close of $111. Two analysts raised targets today alone — Citizens lifted to $177 and HC Wainwright moved to $155 — both maintaining positive ratings after what appears to be a catalyst-driven move. The bull case centres on the Phase 3 VIKTORIA-1 data for gedatolisib in HR+/HER2- breast cancer: positive results in both dosing cohorts represent a genuine clinical milestone in a space short sellers have historically punished on execution risk. Bears counter with a familiar set of concerns — the company generates no revenue, burns cash, and faces a competitive PI3K pathway field where commercial launches routinely disappoint even after clean trial data. The company ended Q1 with cash described as sufficient through 2027, which limits near-term financing risk but doesn't eliminate it.
Institutional ownership adds texture to the bull thesis. Baker Bros. Advisors — a specialist healthcare fund with a strong clinical read-through track record — holds 16.2% of shares, unchanged in the latest reported quarter. RTW Investments added 2.5 million shares in the March quarter, taking its stake to 6.2%. BlackRock and State Street, both updated through June 30, added smaller but meaningful positions. The largest recent insider activity was on the sell side: board member Richard Buller sold shares in multiple tranches in May near $138–143, and a VC-affiliated director sold 25,000 shares the same day. Those moves are worth noting, though the significance scores are low and the stock has since pulled back from those levels.
Prior earnings reactions argue for watching the August 14 print closely. The last two quarterly reports each produced double-digit next-day moves — gains of around 10.6% and 8.1% respectively, extending to 14.5% and 12.6% over five days. A stock with 23% short interest and a history of sharp post-earnings gaps in both directions is the kind of setup where the borrow market's current looseness could tighten fast if the data surprises in either direction.
The key question heading into August is whether the gap between analyst conviction and short-side persistence narrows — and which side the next data point, clinical update, or commercial progress report breaks it toward.
See the live data behind this article on ORTEX.
Open CELC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
